Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $17

Wedbush maintains Stemline Therapeutics (NASDAQ:STML) with a Outperform and lowers the price target from $20 to $17.

Benzinga · 11/11/2019 13:05

Wedbush maintains Stemline Therapeutics (NASDAQ:STML) with a Outperform and lowers the price target from $20 to $17.